Hepatitis C virus core protein induces homotolerance and cross-tolerance to Toll-like receptor ligands by activation of Toll-like receptor 2

Journal of Infectious Diseases

Volumn 202, Issue 6, 2010, Pages 853-861

  Chung, Hobyung ^a   Watanabe, Tomohiro ^b   Kudo, Masatoshi ^a   Chiba, Tsutomu ^b  

^a KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; HEPATITIS C VIRUS CORE PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 3; INTERLEUKIN 10; INTERLEUKIN 12P40; INTERLEUKIN 17; INTERLEUKIN 6; INTERLEUKIN 8; TOLL LIKE RECEPTOR 2; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ANTIGEN PRESENTING CELL; ARTICLE; CD4+ T LYMPHOCYTE; CELL STRAIN HEK293; CONTROLLED STUDY; CROSS TOLERANCE; CYTOKINE PRODUCTION; HEPATITIS C; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; INNATE IMMUNITY; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL;

ANTIGEN-PRESENTING CELLS; CD4-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; IMMUNE TOLERANCE; INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES; INTERLEUKIN-17; INTERLEUKIN-6; LEUKOCYTES, MONONUCLEAR; NF-KAPPA B; TOLL-LIKE RECEPTOR 2; VIRAL CORE PROTEINS;

EID: 77955935168     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/655812     Document Type: Article

References (38)

1. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med 2001; 345:41-52.
2. Dustin LB, Rice CM. Flying under the radar: the immunobiology of hepatitis C. Annu Rev Immunol 2007; 25:71-99.
3. Keller BC, Johnson CL, Erickson AK, Gale M, Jr. Innate immune evasion by hepatitis C virus and West Nile virus. Cytokine Growth Factor Rev 2007; 18:535-544.
4. Foy E, Li K, Sumpter R Jr, et al. Control of antiviral defenses through hepatitis C virus disruption of retinoic acid-inducible gene-I signaling. Proc Natl Acad Sci U S A 2005; 102:2986-2991.
5. Meylan E, Curran J, Hofmann K, et al. Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus.Nature 2005; 437:1167-1172.
6. Li K, Foy E, Ferreon JC, et al. Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage of the Toll-like receptor 3 adaptor protein TRIF. Proc Natl Acad Sci U S A 2005; 102:2992-2997.
7. Loo YM, Owen DM, Li K, et al. Viral and therapeutic control of IFNbeta promoter stimulator 1 during hepatitis C virus infection. Proc Natl Acad Sci U S A 2006; 103:6001-6006.
8. Dienstag JL, McHutchison JG. American Gastroenterological Association technical review on the management of hepatitis C. Gastroenterology 2006; 130:231-264.
9. El-Serag HB, Anand B, Richardson P, Rabeneck L. Association between hepatitis C infection and other infectious diseases: a case for targeted screening? Am J Gastroenterol 2003; 98:167-174.
10. Schuppan D, Afdhal NH. Liver cirrhosis. Lancet 2008; 371:838-851.
11. Riordan SM, Williams R. The intestinal flora and bacterial infection in cirrhosis. J Hepatol 2006; 45:744-757.
12. Akira S, Takeda K. Toll-like receptor signalling. Nat Rev Immunol 2004; 4:499-511.
13. Dolganiuc A, Oak S, Kodys K, et al. Hepatitis C core and nonstructural 3 proteins trigger Toll-like receptor 2-mediated pathways and inflammatory activation. Gastroenterology 2004; 127:1513-1524.
14. Duesberg U, von dem Bussche A, Kirschning C, Miyake K, Sauerbruch T, Spengler U. Cell activation by synthetic lipopeptides of the hepatitis C virus (HCV)-core protein is mediated by Toll-like receptors (TLRs) 2 and 4. Immunol Lett 2002; 84:89-95.
15. Liew FY, Xu D, Brint EK, O'Neill LA. Negative regulation of Toll-like receptor-mediated immune responses. Nat Rev Immunol 2005; 5:446-458.
16. Fichtner-Feigl S, Strober W, Kawakami K, Puri RK, Kitani A. IL-13 signaling through the IL-13a2 receptor is involved in induction of TGF-beta1 production and fibrosis. Nat Med 2006; 12:99-106.
17. Watanabe T, Asano N, Murray PJ, et al. Muramyl dipeptide activation of nucleotide-binding oligomerization domain 2 protects mice from experimental colitis. J Clin Invest 2008; 118:545-559.
18. Watanabe T, Katsukura H, Shirai Y, et al. A liver tolerates a portal antigen by generating CD11c+ cells, which select Fas ligand+ Th2 cells via apoptosis. Hepatology 2003; 38:403-412.
19. Watanabe T, Yoshida M, Shirai Y, et al. Administration of an antigen at a high dose generates regulatory CD4+ T cells expressing CD95 ligand and secreting IL-4 in the liver. J Immunol 2002; 168:2188-2199.
20. Watanabe T, Katsukura H, Chiba T, Kita T, Wakatsuki Y. Periportal and sinusoidal liver dendritic cells suppressing T helper type 1-mediated hepatitis. Gut 2007; 56:1445-1451.
21. Watanabe T, Kitani A, Murray PJ, Strober W. NOD2 is a negative regulator of Toll-like receptor 2-mediated T helper type 1 responses.Nat Immunol 2004; 5:800-808.
22. Sato S, Nomura F, Kawai T, et al. Synergy and cross-tolerance between Toll-like receptor (TLR) 2- and TLR4-mediated signaling pathways. J Immunol 2000; 165:7096-7101.
23. Siedlar M, Frankenberger M, Benkhart E, et al. Tolerance induced by the lipopeptide Pam3Cys is due to ablation of IL-1R-associated kinase- 1. J Immunol 2004; 173:2736-2745.
24. Dobrovolskaia MA, Medvedev AE, Thomas KE, et al. Induction of in vitro reprogramming by Toll-like receptor (TLR)2 and TLR4 agonists in murine macrophages: effects of TLR "homotolerance" versus "heterotolerance" on NF-kappa B signaling pathway components. J Immunol 2003; 170:508-519.
25. Jacinto R, Hartung T, McCall C, Li L. Lipopolysaccharide- and lipoteichoic acid-induced tolerance and cross-tolerance: distinct alterations in IL-1 receptor-associated kinase. J Immunol 2002; 168:6136-6141.
26. Kobayashi K, Hernandez LD, Galan JE, Janeway CA Jr, Medzhitov R, Flavell RA. IRAK-M is a negative regulator of Toll-like receptor signaling.Cell 2002; 110:191-202.
27. McGeachy MJ, Cua DJ. Th17 cell differentiation: the long and winding road. Immunity 2008; 28:445-453.
28. Villacres MC, Literat O, DeGiacomo M, Du W, Frederick T, Kovacs A. Defective response to Toll-like receptor 3 and 4 ligands by activated monocytes in chronic hepatitis C virus infection. J Viral Hepat 2008;15: 137-144.
29. Rodrigue-Gervais IG, Jouan L, Beaule G, et al. Poly(I:C) and lipopolysaccharide innate sensing functions of circulating human myeloid dendritic cells are affected in vivo in hepatitis C virus-infected patients.J Virol 2007; 81:5537-5546.
30. Watanabe T, Kitani A, Murray PJ, Wakatsuki Y, Fuss IJ, Strober W.Nucleotide binding oligomerization domain 2 deficiency leads to dysregulated TLR2 signaling and induction of antigen-specific colitis. Immunity 2006; 25:473-485.
31. Rowan AG, Fletcher JM, Ryan EJ, et al. Hepatitis C virus-specific Th17 cells are suppressed by virus-induced TGF-beta. J Immunol 2008; 181: 4485-4494.
32. Matsusaka T, Fujikawa K, Nishio Y, et al. Transcription factors NF-IL6 and NF-kappa B synergistically activate transcription of the inflammatory cytokines, interleukin 6 and interleukin 8. Proc Natl Acad Sci U S A 1993; 90:10193-10197.
33. Saito T, Gale M Jr. Principles of intracellular viral recognition. Curr Opin Immunol 2007; 19:17-23.
34. Feldmann G, Nischalke HD, Nattermann J, et al. Induction of interleukin- 6 by hepatitis C virus core protein in hepatitis C-associated mixed cryoglobulinemia and B-cell non-Hodgkin's lymphoma. Clin Cancer Res 2006; 12:4491-4498.
35. Grungreiff K, Reinhold D, Ansorge S. Serum concentrations of sIL- 2R, IL-6, TGF-beta1, neopterin, and zinc in chronic hepatitis C patients treated with interferon-a. Cytokine 1999; 11:1076-1080.
36. Shiina M, Rehermann B. Cell culture-produced hepatitis C virus impairs plasmacytoid dendritic cell function. Hepatology 2008; 47:385-395.
37. Iwakura Y, Nakae S, Saijo S, Ishigame H. The roles of IL-17A in inflammatory immune responses and host defense against pathogens.Immunol Rev 2008; 226:57-79.
38. Foster SL, Hargreaves DC, Medzhitov R. Gene-specific control of inflammation by TLR-induced chromatin modifications. Nature 2007; 447:972-978.